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Identification of HTF (HER2 transcription factor) as an AP-2
(activator protein-2) transcription factor and contribution of the
HTF binding site to ERBB2 gene overexpression
Douglas VERNIMMEN, Dominique BEGON, Christophe SALVADOR, Ste! phanie GOFFLOT, Madeleine GROOTECLAES
and Rosita WINKLER1
Molecular Oncology Laboratory, Experimental Cancer Research Center, University of Liege, Sart-Tilman, 4000 Liege, Belgium
The ERBB2 gene is overexpressed in 30% of human breast
cancers and this is correlated with poor prognosis. Over-
expression of the ERBB2 gene is due to increased transcription
and gene amplification. Our previous studies have identified a
new cis element in the ERBB2 promoter which is involved in the
gene’s overexpression. This cis element, located 501 bp upstream
from the main ERBB2 transcription initiation site, binds a
transcription factor called HTF (HER2 transcription factor). We
report here the identification of HTF as an AP-2 (activator
protein-2) transcription factor. The new cis element is bound
by AP-2 with high affinity, compared with a previously described
AP-2 binding site located 284 bp downstream. Co-transfection
INTRODUCTION
The ERBB2 gene, a member of the epidermal growth factor
(EGF) receptor family of genes, is overexpressed in about 30%
of primary human breast cancers, and this represents a negative
prognostic factor for the patient (reviewed in [1]). The ERBB2
gene codes for a 185 kDa transmembrane tyrosine kinase
(p185c-erbB-#). Among the more than 20 growth factors of the
EGF superfamily recognized by these receptors, none binds to
p185c-erbB-# with high affinity. This receptor is activated by
hetero-oligomerization with one of the other ligand-activated
receptors. p185c-erbB-# is the preferred dimerization partner for all
ErbB receptors. Dimers containing p185c-erbB-# are more long-
lived and are more active than all other dimers (reviewed in [2]).
The molecular mechanisms leading to ERBB2 gene over-
expression are gene amplification and increased rates of tran-
scription (reviewed in [3]). Consequently, several groups have
studied ERBB2 promoter activity in breast cancer cells. Gene
reporter constructs have allowed the identification of a number
of positive and negative regulatory elements across the ERBB2
promoter [4]. The ERBB2 promoter is composite, containing two
major transcription initiation sites. One is a classical TATA box,
and the second is an initiator-like element located approx. 40 bp
upstream from the TATA box. It is interesting to note that the
rat neu gene promoter does not contain a TATA box (reviewed
in [5]).
To date, the involvement of only two transcription factor
families has been clearly established in ERBB2 gene over-
expression in breast cancer cell lines. An ets-family transcription
Abbreviations used: AP-2, activator protein-2 ; EGF, epidermal growth factor ; EMSA, electrophoretic mobility-shift assay ; HTF, HER2 transcription
factor.
1 To whom correspondence should be addressed (e-mail rwinkler!ulg.ac.be).
of an AP-2a expression vector with a reporter vector containing
the newly identified AP-2 binding site in front of a minimal
ERBB2 promoter induced a dose-dependent increase in trans-
criptional activity. We examined the contribution of the new AP-
2 binding site to ERBB2 overexpression. For this purpose we
abolished the new and}or the previously described AP-2 binding
sequence by site-directed mutagenesis. The results show that the
two functional AP-2 sites in the first 700 bp of the ERBB2
promoter co-operate to achieve maximal transcriptional activity.
Key words: AP-2 binding site, ERBB2 promoter, HER2 tran-
scription factor, HTF, human, transcription regulation.
factor stimulates expression through a site located immediately
upstream from the TATA box [4]. AP-2 (activator protein-2)
transcription factors stimulate ERBB2 expression and bind to a
sequence located 217 bp upstream from the main transcription
initiation site [6]. AP-2 also controls the expression of at least two
other members of the erbB network, namely ERBB3 [5] and
EGFR (EGF receptor gene) [7]. In primary breast cancers, the
role of AP-2 transcription factors is controversial [8,9].
AP-2 transcription factors form a family of four closely related
and evolutionarily conserved transcription factors : AP-2a, AP-
2b, AP-2c [10] and AP-2d [11]. AP-2 factors show a highly
conserved, original, helix–span–helix dimerization domain pre-
ceded by a helical basic DNA binding domain [12]. AP-2a, AP-
2b and AP-2c bind with similar affinities to GC-rich recognition
sequences.However, whenAP-2 is present in high concentrations,
it can bind to other lower-affinity sites as well [13,14]. The
binding sequence for AP-2d has not yet been well defined [15].
We have described several regions in a 6 kb fragment upstream
from the ERBB2 coding region which modulate the expression of
the gene. Notably, a fragment extending between fi497 and
fi716 bp upstream from the main initiation site strongly activates
transcription in BT-474 cells overexpressing the endogenous
ERBB2 gene [16]. The activating sequence within this fragment
is bound with high affinity by a transcription factor that we have
called HTF (HER2 transcription factor). A good correlation was
observed between HTF levels and ERBB2 overexpression in a
series of breast cancer cell lines [17].
We now show that HTF is identical to AP-2. AP-2a, AP-2b
and AP-2c transcription factors bind the HTF binding site.
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Table 1 Sequences of oligonucleotides used in this study
The boxes denote the AP-2 binding sites. The substituted bases in the mutated oligonucleotides are given in bold and underlined. Missing nucleotides are replaced by hyphens. wt, wild type.
Name Sequence (5«! 3«)
HTF wt 5«-TTCAAAGATTCCAGAAGATATGCCCCGGGGGTCCTGGAAGCC-3«
HTF (A) 5«-TTCAAAGATTCCAGAAGATATGCACCGGGGGTCCTGGAAGCC-3«
HTF (AA/T) 5«-TTCAAAGATTCCAGAAGATATGAACCGTGGGTCCTGGAAGCC-3«
HTF (MCS) 5«-TTCAAAGATTCCAGAAGATATGCC----GGGTCCTGGAAGCC-3«
HTF (M5) 5«-TTCAAAGATTCCAGAAG----GCCCCGGGGGTCCTGGAAGCC-3«
HTF (M3) 5«-TTCAAAGATTCCAGAAGATATGCCCCGGGG----TGGAAGCC-3«
AP2 wt 5«-GAGAACGGCTGCAGGCAACCCAGGCGT-3«
AP2 (T/C) 5«-GAGAACGGCCGCAGGCAACCCAGGCGT-3«
A/H (T/C) 5«-GAGATATGCCGCAGGGAACCCAGGCGT-3«
AP2 (A/T) 5«-GAGAACGGCTGAATGCAACCCAGGCGT-3«
AP2 (AA/T) 5«-GAGAACGGAAGCATGCAACCCAGGCGT-3«
Oct-1 5«-AGGTCGACTCTAGAGGATCCATGCAAATGGATCCCCGGGTACC-3«
Moreover, mutation of either one or both binding sites induces
a comparable decrease in the transcription rate, indicating that
AP-2 has to be bound to both sites to achieve maximal
transcriptional activity.
MATERIALS AND METHODS
Cell lines
BT-474 and ZR75.1 human mammary adenocarcinoma cells and
HCT116 colon carcinoma cells were purchased from A.T.C.C.
(Manassas, VA, U.S.A.) and cultured in the recommended media
supplemented with 10% (v}v) fetal bovine serum, 2 mM glu-
tamine and 100 lg}ml penicillin}streptomycin (BioWhittaker,
Walkersville, MD, U.S.A.).
Electrophoretic mobility-shift assay (EMSA)
Nuclear extracts from BT-474 cells were prepared as described
elsewhere [18]. The sequences containing the HTF [17] and the
AP-2 [19] binding sites, as well as the sequences of the mutant
oligonucleotides (Eurogentec, Seraing, Belgium) used in EMSAs,
are presented in Table 1.
EMSAs were performed as described previously [17]. The
retarded complexes were analysed on a non-denaturing 5%
(w}v) polyacrylamide gel in 0.25‹Tris}borate}EDTA buffer.
For supershift assays, the proteins were incubated overnight at
4 °C in EMSA buffer with 2 ll of an anti-AP-2a antibody (sc-
184; Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.).
Double-stranded oligonucleotides were end-labelled using the
Klenow enzyme (Roche Diagnostic, Basel, Switzerland), incu-
bated with the protein}antibody mixture and analysed as for
EMSAs. The gels were dried and analysed using a
PhosphorImager (Molecular Dynamics).
AP-2 expression vectors [12,20] were in itro translated using
the T’n’T kit (Promega, Madison, WI, U.S.A.).
DNase I footprinting
DNase I footprinting reactions were performed as described
elsewhere [21] with minor modifications. Briefly, a 205 bp frag-
ment was PCR-amplified from p756-HTF wt and HTF (AA}T)
vectors with 5«-TCCTCCCAAATTTGTAGACCCTCT-3« as the
5« primer and 5«-AGCTTGCATCCTACTCCATCCCAAG-3« as
the 3« primer. The fragment was cut by the AccI restriction
enzyme, which recognizes the underlined sequence in the 5«
primer. The resulting 192 bp fragment was purified on an agarose
gel and was end-labelled by fill-in with the Klenow enzyme
(Roche) in the presence of [a-$#P]dCTP (ICN Pharmaceuticals,
Costa Mesa, CA, U.S.A.). The probe (2 ng) was diluted in a total
volume of 25 ll of buffer D [30 mM Tris (pH 7.9), 100 mM KCl,
0.5 mM EDTA, 20% (v}v) glycerol, 0.1% (v}v) Nonidet P40]
containing 1 lg of poly(dI-dC). Samples of 20 lg of nuclear
proteins in buffer D were added in a final volume of 25 ll. The
mixture was incubated for 15 min on ice and then for 2 min at
20 °C. An equal volume of a solution containing 5 mM CaCl
#
and 10 mM MgCl
#
was added, followed by the addition of 1 ll
(0.1–0.4 unit) of freshly diluted DNase I solution (Roche). The
reactions were carried out for 40 s at 20 °C and were stopped by
the addition of 100 ll of STOP solution [1% (w}v) SDS, 200 mM
NaCl, 20 mM EDTA, 10 lg}ml salmon sperm DNA]. The DNA
was extracted and analysed on an 8% (w}v) polyacrylamide}
40% (w}v) urea gel.
Plasmids and constructs
The p756-LUC plasmid has been described previously [16]. The
p86-LUC plasmid was constructed by introducing a
BssHII–HindIII ERBB2 promoter fragment into the pGL3-basic
reporter vector (Promega). p86-HTF wt-LUC and p86-HTF
(AA}T)-LUC were made by inserting a double-stranded DNA
oligonucleotide containing the wild-type or the mutant version of
the AP-2 site into p86-LUC linearized with SacI and BssHII.
The AP-2a expression vector pSPRSV-AP-2 has been described
elsewhere [12].
Site-directed mutagenesis
Site-directed mutagenesis of the p756-LUC vector was performed
using the Chameleon kit (Stratagene, La Jolla, CA, U.S.A.). AP-
2 binding was abolished by changing three bases in the binding
sites (Table 1). The mutations were verified by sequencing.
Transient transfection assays
ZR75.1 and HCT116 cells were transfected using FuGENE 6
reagent (Roche). Cells (4‹10&) were plated on 35 mm tissue
culture dishes, treated with a FuGENE}DNA ratio of 3:1 and
incubated for 48 h in complete medium. Cells were then harvested
and lysed, and the luciferase enzymic activities were measured
using the Luciferase Reporter Gene Assay kit (Roche).
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Western blotting
Samples containing 10 lg of HCT116 cell nuclear extracts were
loaded per well, separated on an SDS}12% (w}v) polyacryamide
gel and transferred to a PVDF membrane (Millipore). An anti-
AP-2a antibody (sc-184; Santa Cruz) was used at a 1:700
dilution. The secondary antibody (DAKO Diagnostic, Glostrup,
Denmark) was detected with the ECL2 system (Amersham}
Pharmacia Biotech).
RESULTS
AP-2 transcription factors bind the HTF cis sequence
We previously described a 44 bp fragment (C4), located fi500 bp
upstream from the main transcription initiation site, which
induces strong activation of ERBB2 transcription in BT-474
cells. We named the putative transcription factor HTF. By
DNase I footprinting experiments, we were able to narrow down
HTF binding to a 17 bp region containing a putative AP-2
binding site (GCCCCGGGG) [17].
To analyse further the identity of HTF, we performed gel
retardation and supershift experiments with BT-474 nuclear
extracts, the HTF probe and an AP-2a-specific antibody (Figure
Figure 1 Binding of the HTF cis sequence by AP-2 transcription factors
(A) EMSA (lanes 1–6 and 13–18) and supershift with anti-AP-2a antibody (lanes 7–12 and 19–24) of BT-474 nuclear protein extracts using HTF or AP-2 probes (see Table 1). The different
competitors (Comp) were used at a 200-fold molar excess. The arrow indicates the supershift and the arrowhead indicates the specific protein–DNA complex. (B) EMSA using wild-type HTF and
AP-2 oligonucleotides (lanes 1 and 3 respectively) and their (AA/T) mutant versions (lanes 2 and 4 respectively). The asterisk indicates the non-specific complex. (C) In vitro synthesized AP-
2a, AP-2b and AP-2c were assayed for binding to the HTF probe by EMSA. (D) DNase I footprinting of a 190 bp PCR fragment containing the HTF binding site. BT-474 nuclear extracts were
used in lanes 2 and 4. In vitro synthesized AP-2a protein was used in lane 6. The wild-type HTF probe was used in lanes 1, 2, 5 and 6, and the (AA/T) mutant version was used in lanes 3
and 4. Lanes 1, 3, and 5 show the control reaction without added proteins. The lanes marked ATGC contain the sequence of the footprinted fragment. FP, footprint.
1A). As a control, we performed the same experiments using the
previously identified proximal AP-2 recognition sequence as a
probe [19]. The sequences of all oligonucleotides used in this work
are shown in Table 1. For the sake of clarity, the newly identified
recognition site will be called HTF, and the sequence identified by
Hollywood and Hurst [19] will be called AP-2. Comparable
retarded complexes were observed with the HTF (Figure 1A,
lanes 1–6) and the AP-2 (Figure 1A, lanes 13–18) probes. Binding
of transcription factors to the HTF and AP-2 sites was compared
by competition with different unlabelled oligonucleotides. The
‘HTF complex’ was completely displaced by unlabelled wild-type
HTF, but not by the HTF (A) oligonucleotide (Figure 1A, lanes
2 and 3). Interestingly, equal amounts of unlabelled wild-type
AP-2 oligonucleotide only partially competed with HTF binding
(lane 4), suggesting a lower affinity for this site. Competitors
containing the AP-2 (A}T) mutant [19] or an Oct-1 binding
site did not interfere with the HTF complex (lanes 5 and 6).
The AP-2 complex was completely displaced by unlabelled wild-
type AP-2 or HTF oligonucleotides (lanes 14 and 16), but not by
the AP-2 (A}T) mutant (lane 15). It is interesting to note that the
unlabelled HTF (A) oligonucleotide partially competed for
the AP-2 complex (lane 17). This result, and our previous
observation that the HTF (A) mutation led to a partial decrease
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Figure 2 AP-2 transcription factors bind with higher affinity to the HTF
sequence than to the AP-2 sequence
(A) Samples of 2 lg of BT-474 crude nuclear proteins were tested by EMSA with HTF and AP-
2 probes. The competitors (Comp) were used at a 100-fold molar excess. The arrowhead
indicates specific protein–DNA complexes, and the asterisk indicates the non-specific complex.
(B) HTF and mutant AP-2 sequences were used as probes in EMSA with 2 lg of BT-474 crude
nuclear proteins. Competitors were used at a 50-fold molar excess.
in the transcriptional activity of the enhancer [17], indicate that
this mutation is not sufficient to abolish AP-2 binding. We thus
designed mutants containing three point mutations (AA}T) in
the HTF and AP-2 sequences. The HTF (AA}T) and AP-2
(AA}T) probes did not give rise to retarded complexes (Figure 1B,
lanes 2 and 4).
To elucidate whether the transcription factor binding the HTF
sequence is indeed AP-2, we performed supershift experiments
with the HTF and AP-2 probes. The anti-AP-2a antibody did
supershift the HTF- and the AP-2-retarded complexes (Figure
1A, lanes 7–12 and 19–24 respectively), showing that AP-2 binds
to the HTF sequence.
To confirm the identity of HTF, we carried out gel retardation
experiments with the HTF probe and in itro translated AP-2a,
AP-2b and AP-2c proteins (Figure 1C). All three proteins bound
specifically to the HTF probe, as shown by using specific and
non-specific competitors (Figure 1C, lanes 2, 3, 5, 6, 8 and 9; see
also below). As further proof, a 192 bp PCR fragment containing
the HTF site was footprinted with in itro translated AP-2a
protein and with crude nuclear extract from BT-474 cells. The
nuclear proteins and the in itro translated AP-2a gave rise to
similar footprints as the wild-type fragment (Figure 1D, lanes 2
and 6 respectively). In contrast, the HTF (AA}T) fragment was
not footprinted by the BT-474 protein extract (Figure 1D, lane
4). Taken together, these results indicate that HTF belongs to the
AP-2 family of transcription factors. Moreover, AP-2 binds with
higher affinity to the HTF site than to the AP-2 site.
Binding affinity of AP-2 for the HTF and AP-2 sites
AP-2 binds the HTF sequence with high affinity, and the C
nucleotide at the third position of the core binding site is vital for
this binding ([17], and see above). The sequences surrounding the
core binding site have been shown to influence the binding of AP-
2 to DNA [7]. Therefore, to better characterize the binding of
AP-2 to the HTF and AP-2 sequences, we performed EMSAs
with both probes and used oligonucleotides containing deletions
of sequences 5« or 3« to the core binding site [HTF (M5) and HTF
(M3) respectively] as competitors. An additional mutant oligo-
nucleotide was synthesized that lacked four nucleotides inside
the core binding site [HTF (MCS); see also Figure 1C]. The HTF
complex was completely abolished in the presence of unlabelled
HTF and HTF (M3) oligonucleotides (Figure 2A, lanes 2 and 6).
In contrast, the HTF (M5) oligonucleotide was only a partial
competitor of the HTF complex, indicating that sequences
located upstream from the core DNA binding site contribute to
the binding of AP-2 to the HTF sequence (Figure 2A, lane 5).
Moreover, the competition with the HTF (A) and HTF (MCS)
mutants did not attenuate the intensity of the HTF complex
(Figure 2A, lanes 3 and 4). The AP-2 complex was completely
displaced by the unlabelled HTF (M5) and HTF (M3) mutants
(Figure 2A, lanes 11 and 12 respectively), but not by the AP-2
(A}T) and HTF (MCS) mutants (lanes 9 and 10). These results
confirm that AP-2 binds to the HTF sequence with a higher
affinity than to the AP-2 sequence (see also Figure 1A). In
addition, they show that the nucleotides located upstream from
the core AP-2 binding site contribute to the high-affinity binding
to the HTF sequence.
Interestingly, the C nucleotide responsible for the high-affinity
binding of the transcription factor to the HTF sequence is
replaced by a T in the AP-2 sequence [19]. We thus tested if the
different binding affinities are due to the differences in the core
binding sites and}or in the flanking sequences. For this purpose,
we replaced the T in the AP-2 sequence by a C, giving the AP-2
(T}C) mutant. In the A}H (T}C) mutant, the AP-2 site was
modified further by replacing the three nucleotides located
immediately upstream from the core binding site with the
corresponding nucleotides from the HTF sequence. An ad-
ditional modification was introduced in this oligonucleotide by
the replacement of the final C in the core binding site by a G.
This mutant sequence thus closely resembles the HTF sequence.
In contrast with AP-2, the AP-2 (T}C) and A}H (T}C) mutants
were efficient competitors of the HTF complex (Figure 2B, lanes
3 and 5). When used as probes, these mutants behave similarly to
the HTF probe, being only partially competed by the unlabelled
wild-type AP-2 probe (Figure 2B, lanes 9 and 14) and almost
completely displaced by unlabelled HTF and by themselves
(Figure 2B, lanes 7, 8, 10 and 12, 13, 15). These experiments
further emphasize the importance of the third C in the core
binding sequence of HTF for the high-affinity binding of AP-2 to
the fragment.
AP-2a activates the ERBB2 proximal promoter through the HTF
sequence
Next we examined the AP-2-dependent enhancer activity of HTF
in io. The HTF and HTF (AA}T) mutant sequences were
cloned in front of a 86 bp ERBB2 minimal promoter in the
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Figure 3 Transcription activation from the HTF site is AP-2-dose-dependent
(A) HCT116 cells were transiently transfected with 0.7 lg of luciferase reporter vectors [p86/p86-HTF (AA/T)/p86-HTF wt] and 0, 0.075, 0.15 and 0.3 lg of the AP-2a expression vector (lanes
2–4, 6–8 and 10–12) in 35 mm tissue culture dishes. Transcriptional activity is expressed as fold induction compared with the level obtained with each vector in the absence of AP-2. The experiment
was repeated three times in triplicate. Luciferase activity in cells transfected with the reporter vector alone was given a value of 1. Data are means‡S.D. of all experiments. (B) AP-2 levels were
measured by Western blotting with 20 lg of nuclear extract from the transfected HCT116 cells. The arrowhead indicates the 50 kDa AP-2a protein. Molecular mass markers (kDa) are indicated
on the left.
Figure 4 Co-operative effect of the two AP-2 sites on ERBB2 promoter
activity
ZR75.1 breast cancer cells were transfected with 1 lg of the wild-type p756-LUC reporter
vector, plus vectors bearing the HTF (AA/T) and AP-2 (AA/T) mutations alone or in combination
(E). Transcriptional activity is expressed as a percentage relative to that with wild-type p756-
LUC. The experiment was repeated three times in triplicate, and data are means‡S.D.
pGL3-basic reporter vector. These vectors were transfected along
with increasing amounts of an AP-2a expression vector into
HCT116 cells expressing very low levels of the endogenous
transcription factor (Figure 3B). Neither the enhancerless pro-
moter (Figure 3A, lanes 1–4) nor the mutant enhancer (Figure
3A, lanes 5–8) showed any significant variation in transcriptional
activity with increasing levels of AP-2a expression vector. In
contrast, the construct containing the wild-type HTF sequence
showed an increase in transcriptional activity which was de-
pendent on AP-2 level (Figure 3A, lanes 9–12). AP-2a protein
amounts are presented in Figure 3(B). This result shows that the
HTF sequence does respond dose-dependently to AP-2 in io.
Co-operation between the HTF and AP-2 sites on a 700 bp
ERBB2 promoter fragment
We have shown previously that the HTF (A) mutation leads to
a 2-fold decrease in p756-LUC reporter vector transcriptional
activity [17]. Therefore we examined more thoroughly the con-
tribution of the HTF site, alone or in combination with the AP-
2 site, to ERBB2 overexpression. We introduced the AA}T
mutation into the AP-2 and HTF sites in p756-LUC reporter
vector. Three vectors were generated, containing the mutation in
each AP-2 site alone, or in both of them. Figure 4 shows the
transcriptional activity of these vectors in ZR75.1 cells. These
cells overexpress ERBB2 and endogenous AP-2a and AP-2c [20].
The triple mutation of the HTF site or the AP-2 site decreased
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transcriptional activity to approx. 20–25% of the wild-type level.
This is in good agreement with previous results showing a
decrease in transcriptional activity following mutation of each
AP-2 binding site alone [17,19]. Interestingly, mutation of
both AP-2 binding sites did not decrease further the transcrip-
tional activity of the 700 bp promoter fragment.
The results presented here (see Figure 3) as well as previously
published data [6] indicate that a single AP-2 binding site is
enough to increase the transcriptional activity of a short promoter
fragment. However, our observations indicate that, in the context
of a 700 bp promoter fragment, both HTF and AP-2 sites must
be functional to allow optimal transcriptional activity of the
ERBB2 promoter.
DISCUSSION
We show in the present paper that the AP-2 transcription factors
bind to the HTF site that we have described previously in the
ERBB2 promoter, and thereby contribute to overexpression of
this gene. Indeed, the HTF nuclear protein complex was super-
shifted by an anti-AP-2 antibody (Figure 1A). Moreover, this
sequence was retarded by in itro translated AP-2a, AP-2b and
AP-2cproteins (Figure 1C). Finally, BT-474 cell nuclear proteins,
as well as in itro translated AP-2a, protected the fragment
containing the HTF site from digestion by DNase I (Figure 1D).
In addition, transfection of a reporter vector containing the HTF
site together with increasing amounts of an AP-2a expression
vector resulted in dose-dependent transcriptional activity (Figure
3). This new AP-2 binding site is thus located 284 nucleotides
upstream from the previously identified AP-2 site [19].
AP-2 transcription factors bind with higher affinity to the
HTF site than to the previously identified AP-2 site in the
ERBB2 promoter (Figure 2). The third C nucleotide in the HTF
core binding site confers high affinity to the binding of AP-2, due
to the low rate of dissociation of the factor from the DNA [17].
When the T present at this position of the AP-2 site was replaced
by a C, the binding affinity of the transcription factor was greatly
increased, as shown by EMSA using this mutant oligonucleotide
as a probe or as a competitor (Figure 2B). This is in good
agreement with the results of Mohibullah and co-workers [13],
who systematically analysed the influence of sequence on AP-2a
binding affinity. These authors also noticed that the T in the
third position reduces the binding of the transcription factor
to the DNA. Moreover, we show that the sequence upstream
from the core binding site also influences binding affinity i.e.,
the presence of an upstream G in the AP-2 sequence decreases
binding affinity. The HTF core sequence is flanked by a T, which
favours binding [13].
The contribution of the two AP-2 binding sites to trans-
criptional activity was analysed by transfecting reporter vectors
containing wild-type or different combinations of mutant AP-2
binding sites in the ERBB2 promoter. The results clearly show
that mutation of either one or both binding sites results in a
similarly low promoter activity, indicating co-operation between
the transcription factor bound to both sites in ZR75.1 cells
expressing high levels of the endogenous AP-2.
Co-operation between AP-2 factors bound to several sites in a
promoter has been reported for several genes. The genes encoding
sodium–potassium co-transporter type 2 [22], placental lactogen
[23] and chorionic gonadotropin [24] are examples where such a
co-operation between AP-2 factors occurs. Moreover, factors
bound to several sites in the pro-a1 (I) collagen gene interact with
each other to form loops that bring the enhancers closer to the
transcription initiation site [25].
In conclusion, we show that AP-2 transcription factors present
a significantly higher affinity for the HTF site than for the
proximal AP-2 site in the ERBB2 gene promoter. It is thus
conceivable that low cellular levels of AP-2 will lead to pref-
erential binding to the high-affinity HTF site, leaving the AP-2
site unoccupied and the promoter poorly active. Only when the
factor is overexpressed will it also bind to the lower-affinity AP-
2 site and, in co-operation with the factor bound to the HTF site,
induce overexpression of the ERBB2 gene. This hypothesis
remains to be tested experimentally.
Recently, the clinical potential of ERBB2 receptor-targeted
therapeutics has been demonstrated [1]. However, receptor-
linked resistance mechanisms now point to the need for ad-
ditional therapeutic alternatives. Strategies that transcriptionally
inhibit ERBB2 promoter activity are particularly appealing,
because ERBB2 gene and transcript targets per cell are fewer in
number than the expressed p185c-erbB-# [4]. Alternatively, ERBB2
promoter activity could be used to increase specifically the
expression of suicide genes in cancer cells [3]. These emerging
ERBB2-promoter-targeted strategies are dependent on a com-
plete under standing of the architecture of the endogenous
ERBB2 promoter and the factors that specify ERBB2 over-
expression [4].
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